{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is MacroGenics, Inc. overvalued or undervalued?
As of March 7, 2024, MacroGenics, Inc. is considered overvalued and risky due to poor financial metrics and a year-to-date return of -46.77%, significantly underperforming its peers and the S&P 500.
Is MacroGenics, Inc. technically bullish or bearish?
As of June 2, 2025, the trend is mildly bearish due to mixed indicators, with weekly MACD and KST showing mild bullishness, while monthly indicators remain bearish and the stock underperforms against the S&P 500.
Who are in the management team of MacroGenics, Inc.?
As of March 2022, the management team of MacroGenics, Inc. includes Dr. Scott Koenig as President and CEO, along with several independent directors, including Mr. Paulo Costa as Chairman.
What does MacroGenics, Inc. do?
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody-based therapies for cancer, autoimmune disorders, and infectious diseases. As of March 2025, it has a market capitalization of $86.43 million, with net sales of $13 million and a net loss of $41 million.
How big is MacroGenics, Inc.?
As of Jun 18, MacroGenics, Inc. has a market capitalization of 86.43 million, with net sales of 154.05 million and a net profit of -55.81 million over the last four quarters. Shareholder's funds are 116.06 million, and total assets amount to 270.56 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
